Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio
Article excerpt
Highlighted: the sentence this signal was extracted from
Basel, 19 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data, including two late-breaking abstracts, across lung, breast and other cancers at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting, held from 23 to 27 October in Madrid. "Our presentations at ESMO 2026 highlight the depth and impact of Roche's oncology pipeline, driven by emerging science capable of bringing new treatment benefits across diverse and high-unmet-need cancers," said Levi Garraway, MD, PhD, Roche's Chief Medical Officer and Head of Global Product Development. "From establishing head-to-head superiority with divarasib in KRAS G12C-mutated lung cancer to advancing patient-centered oral SERD therapies like giredestrant and next-generation ADCs such as Tam-Peli, we are committed to delivering medicines that not only extend life, but also seek to improve treatment experience, tolerability and quality of life for people living with cancer. Divarasib demonstrated superior efficacy and best-in-class potential in KRAS G12C NSCLC Roche will share phase III Krascendo 1 results, which demonstrated divarasib's best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer. Giredestrant data support its potential to become the new standard of care in early-stage and advanced breast cancer Roche will present new data highlighting the...
Keep reading with a free account
The rest of this article, and every signal for Roche, is in your free account.